The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The major reabsorptive mechanism for D-glucose in the kidney is known to involve a low affinity high capacity Na+/glucose cotransporter, which is located in the early proximal convoluted tubule segment S1, and which has a Na+ to glucose coupling ratio of 1:1. Here we provide the first molecular evidence for this renal D-glucose reabsorptive mechanism. We report the characterization of a previously cloned human kidney cDNA that codes for a protein with 59% identity to the high affinity Na+/glucose cotransporter (SGLT1). Using expression studies with Xenopus laevis oocytes we demonstrate that this protein (termed SGLT2) mediates saturable Na(+)-dependent and phlorizin-sensitive transport of D-glucose and alpha-methyl-D-glucopyranoside (alpha MeGlc) with Km values of 1.6 mM for alpha MeGlc and approximately 250 to 300 mM for Na+, consistent with low affinity Na+/glucose cotransport. In contrast to SGLT1, SGLT2 does not transport D-galactose. By comparing the initial rate of [14C]-alpha MeGlc uptake with the Na(+)-influx calculated from alpha MeGlc-evoked inward currents, we show that the Na+ to glucose coupling ratio of SGLT2 is 1:1. Using combined in situ hybridization and immunocytochemistry with tubule segment specific marker antibodies, we demonstrate an extremely high level of SGLT2 message in proximal tubule S1 segments. This level of expression was also evident on Northern blots and likely confers the high capacity of this glucose transport system. We conclude that SGLT2 has properties characteristic of the renal low affinity high capacity Na+/glucose cotransporter as previously reported for perfused tubule preparations and brush border membrane vesicles. Knowledge of the structural and functional properties of this major renal Na+/glucose reabsorptive mechanism will advance our understanding of the pathophysiology of renal diseases such as familial renal glycosuria and diabetic renal disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications
Flier, J. S., Underhill, L. H., Brownlee, M., Cerami, A., & Vlassara, H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805193182007 · Cited by 2,511
SV40-transformed simian cells support the replication of early SV40 mutants
Gluzman, Y. (1981) · Cell · doi:10.1016/0092-8674(81)90282-8 · Cited by 2,372
Primary structure and functional characterization of a high-affinity glutamate transporter
Kanai, Y., & Hediger, M. A. (1992) · Nature · doi:10.1038/360467a0 · Cited by 1,332
Self-citationExpression cloning and cDNA sequencing of the Na+/glucose co-transporter
Hediger, M. A., Coady, M. J., Ikeda, T. S., & Wright, E. M. (1987) · Nature · doi:10.1038/330379a0 · Cited by 1,004
Self-citationGlucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter
Turk, E., Zabel, B., Mundlos, S., Dyer, J., & Wright, E. M. (1991) · Nature · doi:10.1038/350354a0 · Cited by 383
Mager, S., Naeve, J., Quick, M., Labarca, C., Davidson, N., & Lester, H. A. (1993) · Neuron · doi:10.1016/0896-6273(93)90309-f · Cited by 325
Electrogenic properties of the cloned Na+/glucose cotransporter: I. Voltage-clamp studies
Parent, L., Supplisson, S., Loo, D. F., & Wright, E. (1992) · The Journal of Membrane Biology · doi:10.1007/bf00235797 · Cited by 251
Homology of the human intestinal Na+/glucose and Escherichia coli Na+/proline cotransporters.
Hediger, M. A., Turk, E., & Wright, E. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5748 · Cited by 242
Self-citationRelaxation kinetics of the Na+/glucose cotransporter.
Loo, D. D., Hazama, A., Supplisson, S., Turk, E., & Wright, E. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5767 · Cited by 231
Cited by
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Expression cloning of a mammalian proton-coupled oligopeptide transporter
Fei, Y.-J., Kanai, Y., Nussberger, S., Ganapathy, V., Leibach, F. H., Romero, M. F., Singh, S. K., Boron, W. F., & Hediger, M. A. (1994) · Nature · doi:10.1038/368563a0 · Cited by 891
Self-citationGlucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
“A second Na+–glucose transporter, SGLT2, is of low affinity and is predominantly expressed on the apical membrane of renal convoluted proximal tubules (S1 and S2 cells) (Wells et al. 1992; Kanai et al. 1994).”
BackgroundSodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
“’ For the three patients in the placebo group, (1) the patient had insulin regimen altered, which is against the protocol guidance, (2) the patient met discontinuation criteria for sustained elevated serum creatinine, and (3) the patient was inappropriately randomized with a high screening potassium and removed a few…”
BackgroundMeng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Vallon, V., Platt, K. A., Cunard, R., Schroth, J., Whaley, J., Thomson, S. C., Koepsell, H., & Rieg, T. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010030246 · Cited by 563
Jonas, J.-C., Sharma, A., Hasenkamp, W., Ilkova, H., Patanè, G., Laybutt, R., Bonner-Weir, S., & Weir, G. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14112 · Cited by 559
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Functional Properties and Genomics of Glucose Transporters
Zhao, F.-Q., & Keating, A. (2007) · Current Genomics · doi:10.2174/138920207780368187 · Cited by 549
The pathophysiology of hypertension in patients with obesity
DeMarco, V. G., Aroor, A. R., & Sowers, J. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.44 · Cited by 545
Utsunomiya-Tate, N., Endou, H., & Kanai, Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.14883 · Cited by 529
Self-citationGlucose Transporter Isoforms GLUT1 and GLUT3 Transport Dehydroascorbic Acid
Rumsey, S. C., Kwon, O., Xu, G. W., Burant, C. F., Simpson, I., & Levine, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18982 · Cited by 473
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Han, S., Hagan, D. L., Taylor, J. R., Xin, L., Meng, W., Biller, S. A., Wetterau, J. R., Washburn, W. N., & Whaley, J. M. (2008) · Diabetes · doi:10.2337/db07-1472 · Cited by 421
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Rosenstock, J., Vico, M., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 408
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Chino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., & Tamai, I. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1909 · Cited by 389
Nomura, S., Sakamaki, S., Hongu, M., Kawanishi, E., Koga, Y., Sakamoto, T., Yamamoto, Y., Ueta, K., Kimata, H., Nakayama, K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100332n · Cited by 385
SLC2A9 Is a High-Capacity Urate Transporter in Humans
Caulfield, M. J., Munroe, P. B., O'Neill, D., Witkowska, K., Charchar, F. J., Doblado, M., Evans, S., Eyheramendy, S., Onipinla, A., Howard, P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050197 · Cited by 378
Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 363
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 361
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4656-5 · Cited by 348
Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
Santer, R., & Calado, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010609 · Cited by 343
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Chen, J., Williams, S., Ho, S., Loraine, H., Hagan, D., Whaley, J. M., & Feder, J. N. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0006-4 · Cited by 307
Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria
Santer, R., Kinner, M., Lassen, C. L., Schneppenheim, R., Eggert, P., Bald, M., Brodehl, J., Daschner, M., Ehrich, J. H. H., Kemper, M., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092790.89332.d2 · Cited by 305
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Vrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., Radović, N., Jadrijević, S., Aleksic, I., Walles, T., et al. (2015) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1619-7 · Cited by 290
Jabbour, S. A., Hardy, E., Sugg, J., Parikh, & for the Study 10 Group (2014) · Diabetes Care · doi:10.2337/dc13-0467 · Cited by 286
Han, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281
“Sodium/glucose cotransporter 2 (SGLT2), a 672 amino acid transporter, is mainly expressed within the proximal tubule of the kidney and is reported to be responsible for approximately 90% of renal glucose reabsorption [1].”
BackgroundGlucose transport by human renal Na + / d -glucose cotransporters SGLT1 and SGLT2
Hummel, C. S., Lu, C., Loo, D. D. F., Hirayama, B. A., Voss, A. A., & Wright, E. M. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00388.2010 · Cited by 270
Lee, W. S., Kanai, Y., Wells, R. G., & Hediger, M. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32677-7 · Cited by 268
Self-citationKatsuno, K., Fujimori, Y., Takemura, Y., Hiratochi, M., Itoh, F., Komatsu, Y., Fujikura, H., & Isaji, M. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110296 · Cited by 267
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Nair, S., & Wilding, J. P. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0473 · Cited by 263
Aminoglycoside-Induced Cochleotoxicity: A Review
Jiang, M., Karasawa, T., & Steyger, P. S. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00308 · Cited by 261
Pathophysiology of the Diabetic Kidney
Vallon, V., & Komers, R. (2011) · Comprehensive Physiology · doi:10.1002/cphy.c100049 · Cited by 259
Industrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
Milligan, P. A., Brown, M. J., Marchant, B., Martin, S. W., van der Graaf, P. H., Benson, N., Nucci, G., Nichols, D. J., Boyd, R. A., Mandema, J. W., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.54 · Cited by 238
Anti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182
Wilcox, C. S., Shen, W., Boulton, D. W., Leslie, B. R., & Griffen, S. C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007046 · Cited by 139
Lee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J. (2021) · Journal of Immunology Research · doi:10.1155/2021/9944880 · Cited by 139
Ohara, K., Masuda, T., Murakami, T., Imai, T., Yoshizawa, H., Nakagawa, S., Okada, M., Miki, A., Myoga, A., Sugase, T., et al. (2019) · Nephrology · doi:10.1111/nep.13552 · Cited by 81
Developmental changes in renal tubular transport-an overview
Gattineni, J., & Baum, M. (2015) · Pediatric Nephrology · doi:10.1007/s00467-013-2666-6 · Cited by 73
Liu, D.-Z., Sinchaikul, S., Reddy, P. V. G., Chang, M.-Y., & Chen, S.-T. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.008 · Cited by 53
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35
Sawada, Y., Izumida, Y., Takeuchi, Y., Aita, Y., Wada, N., Li, E., Murayama, Y., Piao, X., Shikama, A., Masuda, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.081 · Cited by 31
Metadata
- Authors
- Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A.
- Venue
- Journal of Clinical Investigation
- Published
- 1994-01-01
- Volume
- 93
- Issue
- 1
- Pages
- 397-404
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2149185387
- Cited by
- 630
- References
- 33
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.